Biohaven (BHVN) Projected to Post Earnings on Thursday

Biohaven (NYSE:BHVN - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Biohaven to post earnings of ($1.64) per share and revenue of $1.25 million for the quarter.

Biohaven (NYSE:BHVN - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). On average, analysts expect Biohaven to post $-9 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Biohaven Stock Performance

Biohaven stock opened at $22.14 on Thursday. The stock has a 50-day moving average of $25.44 and a two-hundred day moving average of $36.98. Biohaven has a one year low of $15.79 and a one year high of $55.70. The stock has a market cap of $2.26 billion, a PE ratio of -2.37 and a beta of 1.33.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $54.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. JPMorgan Chase & Co. cut their price objective on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Robert W. Baird cut their price objective on Biohaven from $60.00 to $57.00 and set an "outperform" rating on the stock in a report on Monday. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the company a "buy" rating in a report on Thursday, March 20th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price objective on shares of Biohaven in a report on Tuesday, March 4th. Fourteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $62.54.

Insider Activity

In other Biohaven news, Director John W. Childs bought 32,700 shares of Biohaven stock in a transaction dated Tuesday, March 4th. The stock was acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the transaction, the director now directly owns 2,320,571 shares of the company's stock, valued at approximately $70,707,798.37. This represents a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 16.00% of the company's stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.